 |
|
Clozapine Is Better Tolerated in Younger Patients: Risk Factors for Discontinuation from a Nationwide Database in Japan
Katsunori Toyoda, Takeo Hata, Shigeru Yamauchi, Shinya Kinoshita, Masami Nishihara, Kazuhisa Uchiyama, Ken Inada, Tetsufumi Kanazawa
Psychiatry Investig. 2021;18(2):101-109. Published online 2021 Jan 19 DOI: https://doi.org/10.30773/pi.2020.0376
|
|
Side effects of clozapine in older adults with treatment‐resistant schizophrenia compared to younger adults
Floor C. E. Groenewald, Rob M. Kok
International Journal of Geriatric Psychiatry.2024;[Epub] CrossRef High rates of myocarditis with clozapine in the Hunter region of Australia
Srinivasan Tirupati, Mahinda K. Arachchi
Schizophrenia Research.2024; 264: 543. CrossRef Dropout rates and reasons for dropout among patients receiving clozapine
Sandeep Grover, Eepsita Mishra, Subho Chakrabarti
Indian Journal of Psychiatry.2023; 65(6): 680. CrossRef Data Mining for Risks of Clozapine Side Effects, Including Neutropenia, Associated with Lithium Carbonate Administration: Analysis Using the Japanese Adverse Drug Event Report Database
Yuichi Uwai, Tomohiro Nabekura
Drugs - Real World Outcomes.2023; 10(3): 481. CrossRef Current practice for clozapine-induced leukopenia in Japanese psychiatric hospitals: A nationwide survey
Tomihisa Niitsu, Norio Yasui-Furukori, Ken Inada, Tetsufumi Kanazawa, Masaomi Iyo, Takefumi Ueno, Ryota Hashimoto
Schizophrenia Research.2023;[Epub] CrossRef Safety profile of clozapine: Analysis using national registry data in Japan
Shinichi Imazu, Takeo Hata, Katsunori Toyoda, Yoichiro Kubo, Shigeru Yamauchi, Shinya Kinoshita, Masami Nishihara, Ken Inada, Tetsufumi Kanazawa
Journal of Psychiatric Research.2021; 141: 116. CrossRef
|